Abstract
This Feature will introduce the strategies of therapeutic antibodies (mAbs) in-depth characterization by mass spectrometry (MS) and discuss analytical comparison of biosimilar to originator mAbs, with the cases of trastuzumab and cetuximab. In addition, the structural and functional insights gained both by state-of-the art and emerging MS methods used for biobetters and next generation antibodies design and optimization will also be highlighted.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antibodies, Bispecific / analysis*
-
Antibodies, Monoclonal / analysis
-
Antibodies, Monoclonal, Humanized / analysis
-
Biosimilar Pharmaceuticals / analysis*
-
Cetuximab
-
Humans
-
Immunoconjugates / analysis*
-
Immunoglobulin Fab Fragments / analysis*
-
Immunoglobulin G / analysis*
-
Mice
-
Protein Engineering
-
Spectrometry, Mass, Electrospray Ionization
-
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
-
Spectroscopy, Fourier Transform Infrared
-
Trastuzumab
Substances
-
Antibodies, Bispecific
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Biosimilar Pharmaceuticals
-
Immunoconjugates
-
Immunoglobulin Fab Fragments
-
Immunoglobulin G
-
Trastuzumab
-
Cetuximab